Literature DB >> 6814473

Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.

W E Perkins, R L Schroeder, R A Carrano, A R Imondi.   

Abstract

ICRF-187 was tested for cardioprotective activity in doxorubicin-treated mice and guinea pigs. Pretreatment with i.p. ICRF-187 caused a significant decrease in the indicence of i.v. doxorubicin-induced myocardial histological damage in the mouse. I.p. ICRF-187 did not, however, reduce the effect of i.p. doxorubicin on a functional myocardial effect of this antitumour drug, a reduced histamine responsiveness of right atria in vitro. These data suggest that ICRF-187 may not be specific for all the cardiac effects of doxorubicin.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6814473      PMCID： PMC2011185          DOI： 10.1038/bjc.1982.251

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  6 in total

1.  The interval-force relationship: a technique for evaluating the cardiac toxicity of anthracycline analogs.

Authors:  J G Breed; A N Zimmerman; F L Meyler; H M Pinedo
Journal:  Cancer Treat Rep       Date:  1979-05

2.  Nuclear and mitochondrial effects of adriamycin in singly isolated pulsating myocardial cells.

Authors:  T J Lampidis; G Moreno; C Salet; F Vinzens
Journal:  J Mol Cell Cardiol       Date:  1979-04       Impact factor: 5.000

3.  Influence of adriamycin on calcium exchangeability in cardiac muscle and its modification by ouabain.

Authors:  F Villani; F Piccinini; P Merelli; L Favalli
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

4.  Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187).

Authors:  E H Herman; V J Ferrans
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

5.  Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse.

Authors:  C Bertazzoli; O Bellini; U Magrini; M G Tosana
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

6.  Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.

Authors:  E H Herman; V J Ferrans; W Jordan; B Ardalan
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1981-01
  6 in total
  5 in total

1.  Relative cardiotoxicity and cytotoxicity of anthraquinonyl glucosaminosides.

Authors:  J W Banning; H N Abramson; H C Wormser; J D Wu; T H Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.

Authors:  J R Baldwin; B A Phillips; S K Overmyer; N Z Hatfield; P K Narang
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.

Authors:  P Jakobsen; B Sørensen; L Bastholt; M R Mirza; S B Gjedde; H T Mouridsen; C Rose
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.

Authors:  B Sørensen; L Bastholt; M R Mirza; S B Gjedde; P Jakobsen; H T Mouridsen; C Rose
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.

Authors:  J Zhang; E H Herman; V J Ferrans
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.